Hengrui Medicine's new adaptation to the "Apatini tablets of methulphate" has been approved: the treatment of hepatocellular carcinoma

Recently, Hengrui Pharmaceutical apatinib tablet new adaptive (chemical class 2.4) listing application (acceptance number: CXHS2000004) was approved by NMPA for the treatment of patients with advanced hepatocellular carcinoma who have failed or are insulable after receiving at least first-line systemic treatment.
this is the second adaptation approved by Apatini.
a Phase III clinical (NCT02329860) study for patients who have previously received at least one line of systemic treatment (solafinie and oxalipal) failure or inability to withstand advanced hepatocellular carcinoma Compared to the placebo group, the total survival of the apatinib group was significantly extended (8.7 vs. 6.8 months) and the risk of death was reduced in patients (HR:0.785, p=0.0476).
the Apatini group significantly extended the progression-free lifetime (4.5 vs. 1.9 months, HR:0.471, 0.0001) significantly increased the objective mitigation rate (10.7 percent vs. 1.5 percent).
safety, the most common ≥ incidence of adverse reactions above level 3 was hypertension (71 cases in the Apatini group (27.6%) vs placebo group 3 (2.3%)), hand-foot syndrome (46 (17.9%) vs 0), reduced platea count (34 (13.2%) vs 1 (0.8%)), reduced neutral granulocyte count (27 (10.5%)vs 0).
Methadone Apatini is a class 1 small molecule developed by Hengrui to target vascular endoderial cell growth factor recipient 2 (VEGFR-2) tyrosine kinase inhibitors, first approved by NMPA in 2014 for the treatment of patients with advanced gastric adenocarcinoma or gastroesophageal congenerative adenocarcinoma who have progressed or relapsed after at least 2 systematic chemotherapy.
In addition, apatinib monodone drugs or in combination with carelli pearl monoanti, fluorine parri, SHR-1210 or etoposide softgels to treat breast cancer, ovarian cancer, non-small cell lung cancer a variety of solid tumor adaptation has been in the clinical development stage.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here